Citations

Showing 10 of 108094 citations.

Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial
Almario, Christopher V. , Deen, Welmoed K. van , Gale, Rebecca, Sidorkiewicz, Stéphanie , Choi, So Yung , Bonthala, Nirupama , Ha, Christina , Syal, Gaurav , Dupuy, Taylor , Melmed, Gil , Spiegel, Brennan , Melmed, Gil Y , Spiegel, Brennan , Chen, Michelle , Liu, Xiaoyu

Mayo Clinic

American Journal of Gastroenterology | June 13, 2022 | Volume: 117 | Issue: 9 | Pages: 1508-1518

10.14309/ajg.0000000000001866 | PMID 35973146 Get It

INTRODUCTION: To support shared decision-making (SDM) between patients and providers surrounding biologic treatments, we created IBD&me (ibdandme.org)—a freely available, unbranded, interactive decision aid. We performed a multicenter comparative effectiveness trial comparing the impact of IBD&me on SDM vs a biologics fact sheet developed by the Crohn's & Colitis Foundation. METHODS: We enrolled patients with inflammatory bowel disease (IBD) being seen at a clinic within IBD Qorus—a multicenter adult IBD learning health system—between March 5, 2019, and May 14, 2021. Eligible patients included those with recent IBD-related symptoms who reported that they wanted to discuss biologics with their provider during their upcoming visit. Patients were randomized 1:1 using stratified block randomization and received an e-mail 1 week before their visit inviting them to review either IBD&me or a fact sheet. The primary outcome was patient perception of SDM as measured by the 9-Item SDM Questionnaire (0–100 scale; higher = better); the Student t test was used to compare outcomes between arms. RESULTS: Overall, 152 patients were randomized (biologics fact sheet 75, IBD&me 77); most patients had Crohn's disease (66.4%) and were biologic-experienced (82.9%). No differences were seen between groups regarding SDM (fact sheet 72.6 ± 25.6, IBD&me 75.0 ± 20.8; P = .57). Most patients stated they would be likely to recommend the fact sheet (79.6%) or IBD&me (84.9%; P = .48) to another patient with IBD. DISCUSSION: No differences in outcomes were seen between IBD&me and the biologics fact sheet in this comparative effectiveness study; patients reported high satisfaction with both resources. Further study, particularly among biologic naïve patients, is needed to determine the utility of interactive components to IBD decision aids.
Lung Infection in Severe Alcohol-related Hepatitis: Not to be Underestimated
Kamath, Patrick S. , Gonzalez, Stevan A

Mayo Clinic

American Journal of Gastroenterology | June 13, 2022 | Volume: 117 | Issue: 7 | Pages: 1044-1045

10.14309/ajg.0000000000001864 | PMID 35765906 Get It

Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
Abeykoon, Jithma P. , Kumar, Shaji , Malave, Gabriella C., Young, Kimberly , Ailawadhi, Sikander , Larsen, Jeremy T. , Muchtar, Eli , Kourelis, Taxiarchis , Warsame, Rahma , Bergsagel, Leif, Lacy, Martha Q. , Kapoor, Prashant , Bergsagel, P. Leif , Bergsagel, P. Leif , Vaxman, Iuliana , Kumar, Shaji K , Young, Kimberly S, Ailawadhi, Sikander , Muchtar, E , Gonsalves, Wilson , Kourelis, Taxiarchis , Leung, Nelson , Vaxman, Iuliana , Patel, Sanjay V. , Malave, Gabriella C, Young, Kimberly S., Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

British Journal of Haematology | June 13, 2022 | Volume: 199 | Issue: 1 | Pages: 95-99

10.1111/bjh.18298 | PMID 35694818 Get It

SummaryBelantamab mafodotin (BLMF) is a B‐cell maturation antigen‐directed antibody‐drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF‐induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity‐related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2–not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.
Prospective evaluation of lymphatic embolization as part of the treatment in dogs with presumptive idiopathic chylothorax
Carvajal, Jose L. , Case, J. Brad , Grosso, Federico R. Vilaplana , Fox‐Alvarez, W. Alexander, Regier, Penny J. , Verpaalen, Valentine D. , Toskich, Beau B. , Verpaalen, Valentine

Mayo Clinic

Veterinary Surgery | June 13, 2022 | Volume: 51 | Issue: S1 | Pages: No page available

10.1111/vsu.13825 | PMID 35692101 Get It

AbstractObjectiveTo describe the embolization technique and short‐term clinical outcome in dogs undergoing lymphatic embolization (LE) as part of treatment for presumptive idiopathic chylothorax (IC). Additionally, to document findings in computed tomography lymphangiography (CTLa) following embolization.Study designProspective case series.AnimalsEight client‐owned dogs.MethodsDogs underwent CTLa followed by thoracic duct ligation (TDL), pericardiectomy (PC) and LE. A mixture of 3:1 lipiodol: n‐butyl cyanoacrylate embolic solution was injected through a catheterized mesenteric lymphatic vessel via limited abdominal approach using intraoperative fluoroscopy. CTLa was scheduled for 12 weeks postoperatively, and long‐term follow‐up was obtained via telephone contact.ResultsLE was technically successful in six of the eight dogs; and clinically successful in five of the six dogs. In the unsuccessful dog, a diagnosis of lymphangiosarcoma was determined, and the owners elected for euthanasia. Five dogs who underwent successful LE underwent CTLa at 12 weeks. Complete resolution of pleural effusion occurred in three dogs and scant pleural effusion in two dogs. A robust lymphatic embolus preventing antegrade continuation of radiocontrast was documented in all five dogs. Five of the six dogs that underwent LE, were alive and clinically normal at 358–960 days postoperatively.ConclusionsLE is a feasible part of treatment for dogs with IC. Additionally, a robust lymphatic embolus and lack of radiocontrast flow past the embolus was documented at 12 weeks following surgery.Clinical significanceLE has the potential to reduce surgical failure by reducing efferent lymphatic chyle flow, occluding missed lymphatic branches and preventing the development of collateral branches.
Efficacy and safety of SOFIA aspiration catheter for mechanical thrombectomy via ADAPT and Solumbra echniques in acute ischemic stroke: A systematic review and meta-analysis
Essibayi, Muhammed Amir , Brinjikji, Waleed , Essibayi, Muhammed Amir

Mayo Clinic

Interventional Neuroradiology | June 13, 2022 | Volume: 30 | Issue: 3 | Pages: 326-335

10.1177/15910199221107438 | PMID 35695222 Get It

Introduction SOFIA catheter is a relatively new and recently FDA-approved aspiration catheter. This systematic review aims to investigate the safety and efficacy of SOFIA catheter for treatment of acute ischemic stroke (AIS) via ADAPT and Solumbra techniques. Methods Search of all studies evaluating the SOFIA catheter for mechanical thrombectomy (MT) for treatment of AIS via ADAPT and Solumbra techniques from inception through 2020 on Pubmed, PMC, and Embase was performed. We analyzed the angiographic and clinical outcomes of both techniques with SOFIA catheter using the random-effects model. Results From 18 studies, 1836 patients were included with 1365 receiving MT using ADAPT and 471 with solumbra technique. The mean age was 69.8 years and 51.1% of the patients were women. The rate of rescue therapy was 30%. The outcomes rates of ADAPT group were as follows; mFPE (59.3%), FPE (34.4%) final TICI 2b/3 (89.3%), procedural complications (8%), embolization to new territory (ENT) (2.3%), symptomatic ICH (5.4%), mean NIHSS (8.97), 90-day-mRS 0–2 (48.8%), and mortality (15.3%). The outcomes rates of Solumbra group were as follows; mFPE (60.5%), FPE (46.7%), final TICI 2b/3 (93%), procedural complications (6.4%), ENT (2%), symptomatic ICH (6%), mean NIHSS (7.59), mRS 0–2 (53.8%), and mortality (10.8%). ICA and posterior circulation strokes, and tandem lesions had worse outcomes (P < .005). MCA strokes were associated with better outcomes (P = .005). ASPECT scores’ association with the clinical outcomes was found statistically significant. Conclusion SOFIA catheter is effective and safe to treat acute ischemic stroke regardless of applied MT technique.
VPI Management in SATB2 Syndrome: Use of MRI to Evaluate Anatomy and Physiology in Non-Cleft VPI
Perry, Jamie L. , Chee-Williams, Jessica L. , Snodgrass, Taylor D. , Sitzman, Thomas J. , Sitzman, Thomas J , Chee-Williams, Jessica L , Snodgrass, Taylor , Perry, Jamie L

Mayo Clinic

The Cleft Palate Craniofacial Journal | June 13, 2022 | Volume: 60 | Issue: 11 | Pages: 1499-1504

10.1177/10556656221106888 | PMID 35695193 Get It

This clinical case study describes the velopharyngeal anatomy and physiology in a patient who presented with SATB2-associated syndrome (SAS) and velopharyngeal insufficiency (VPI) in the absence of an overt cleft palate. The clinical presentation, treatment, outcome, and the contribution of anatomical findings from MRI to surgical treatment planning for this rare genetic disorder, SAS, are described. This case study contributes to our current understanding of the anatomy and physiology of the velopharyngeal mechanism in an individual born with SAS and non-cleft VPI. It also details the changes following bilateral buccal myomucosal flaps in this patient.
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
Ordóñez‐Reyes, Camila , García-Robledo, Juan Esteban , Chamorro, Diego F. , Mosquera, Andrés , Sussmann, Liliana, Ruíz-Patiño, Alejandro , Arrieta, Óscar , Zatarain-Barrón, Lucía, Rojas, Leonardo , Russo, Alessandro , Miguel‐Pérez, Diego de , Cardona, Andrés F. , de Miguel-Perez, Diego , Arrieta, Oscar , Cardona, Andrés F , Chamorro Ortiz, Diego Fernando , Ordóñez-Reyes, Camila , Garcia-Robledo, Juan Esteban , Rojas, Leonardo , Rolfo, Christian

Mayo Clinic

Pharmaceutics | June 12, 2022 | Volume: 14 | Issue: 6 | Pages: 1243

10.3390/pharmaceutics14061243 | PMID 35745815 Get It

Immunotherapy has redefined the treatment of cancer patients and it is constantly generating new advances and approaches. Among the multiple options of immunotherapy, bispecific antibodies (bsAbs) represent a novel thoughtful approach. These drugs integrate the action of the immune system in a strategy to redirect the activation of innate and adaptive immunity toward specific antigens and specific tumor locations. Here we discussed some basic aspects of the design and function of bsAbs, their main challenges and the state-of-the-art of these molecules in the treatment of hematological and solid malignancies and future perspectives.
APOE ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease
Singh, Neha Atulkumar , Tosakulwong, Nirubol , Graff‐Radford, Jonathan , Pham, Nha Trang Thu, Sintini, Irene , Weigand, Stephen D. , Senjem, Matthew L. , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Senjem, Matthew L , Singh, Neha Atulkumar , Machulda, Mary M. , Schwarz, Christopher G. , Carrasquillo, Minerva M. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | June 12, 2022 | Volume: 19 | Issue: 3 | Pages: 784-796

10.1002/alz.12711 | PMID 35691047 Get It

AbstractIntroductionApolipoprotein E (APOE) ε4 is an important genetic risk factor for typical Alzheimer's disease (AD), influencing brain volume and tau burden. Little is known about its influence in atypical presentations of AD.MethodsAn atypical AD cohort of 140 patients diagnosed with either posterior cortical atrophy or logopenic progressive aphasia underwent magnetic resonance imaging and positron emission tomography. Linear mixed effects models were fit to assess the influence of APOE ε4 on cross‐sectional and longitudinal regional metrics.ResultsAt baseline, APOE ε4 carriers had smaller hippocampal and amygdala volumes and greater tau standardized uptake volume ratio in the hippocampus and entorhinal cortex compared to non‐carriers while longitudinally, APOE ε4 non‐carriers showed faster rates of atrophy and tau accumulation in the entorhinal cortex, with faster tau accumulation in the hippocampus.DiscussionAPOE ε4 influences patterns of neurodegeneration and tau deposition and was associated with more medial temporal involvement, although there is evidence that non‐carriers may be catching up over time.
Enhancing the Trustworthiness of the Endocrine Society’s Clinical Practice Guidelines
McCartney, Christopher R. , Corrigan, Maureen D. , Drake, Matthew T. , Fuleihan, Ghada El‐Hajj , Korytkowski, Mary T. , Lash, Robert W. , Lieb, David C. , McCall, Anthony L. , Muniyappa, Ranganath , Piggott, Thomas , Schünemann, Holger J. , El-Hajj Fuleihan, Ghada , Schünemann, Holger J , Wiercioch, Wojtek , McDonnell, Marie E , Murad, M Hassan , Drake, Matthew T , Muniyappa, Ranganath , McCartney, Christopher R , Piggott, Thomas , Santesso, Nancy A. , Wiercioch, Wojtek , McDonnell, Marie E. , Murad, M. Hassan

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 12, 2022 | Volume: 107 | Issue: 8 | Pages: 2129-2138

10.1210/clinem/dgac290 | PMID 35690966 Get It

Abstract In an effort to enhance the trustworthiness of its clinical practice guidelines, the Endocrine Society has recently adopted new policies and more rigorous methodologies for its guideline program. In this Clinical Practice Guideline Communication, we describe these recent enhancements—many of which reflect greater adherence to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to guideline development—in addition to the rationale for such changes. Improvements to the Society’s guideline development practices include, but are not limited to, enhanced inclusion of nonendocrinologist experts, including patient representatives, on guideline development panels; implementation of a more rigorous conflict/duality of interest policy; a requirement that all formal recommendations must be demonstrably underpinned by systematic evidence review; the explicit use of GRADE Evidence-to-Decision frameworks; greater use and explanation of standardized guideline language; and a more intentional approach to guideline updating. Lastly, we describe some of the experiential differences our guideline readers are most likely to notice.
A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline for the Management of Hyperglycemia in Adults Hospitalized for Noncritical Illness or Undergoing Elective Surgical Procedures
Seisa, Mohamed O. , Saadi, Samer , Nayfeh, Tarek , Muthusamy, Kalpana , Shah, Sahrish, Jawaid, Tabinda , Abd‐Rabu, Rami , Antinori-Lent, Kellie, Donihi, Amy C. , Drincic, Andjela, Luger, Anton, Roldan, Victor D. Torres , Urtecho, Meritxell , Shah, Sahrish H, Hasan, Bashar , Abd-Rabu, Rami, Muniyappa, Ranganath , Torres Roldan, Victor D , Nayfeh, Tarek , Saadi, Samer , Firwana, Mohammed , Hasan, Bashar , Korytkowski, Mary T. , Muniyappa, Ranganath , Wang, Zhen , Murad, M. Hassan

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 12, 2022 | Volume: 107 | Issue: 8 | Pages: 2139-2147

10.1210/clinem/dgac277 | PMID 35690929 Get It

AbstractContextIndividuals with diabetes or newly recognized hyperglycemia account for over 30% of noncritically ill hospitalized patients. Management of hyperglycemia in these patients is challenging.ObjectiveTo support development of the Endocrine Society Clinical Practice Guideline for management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures.MethodsWe searched several databases for studies addressing 10 questions provided by a guideline panel from the Endocrine Society. Meta-analysis was conducted when feasible. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess certainty of evidence.ResultsWe included 94 studies reporting on 135 553 patients. Compared with capillary blood glucose, continuous glucose monitoring increased the number of patients identified with hypoglycemia and decreased mean daily blood glucose (BG) (very low certainty). Data on continuation of insulin pump therapy in hospitalized adults were sparse. In hospitalized patients receiving glucocorticoids, combination neutral protamine hagedorn (NPH) and basal-bolus insulin was associated with lower mean BG compared to basal-bolus insulin alone (very low certainty). Data on NPH insulin vs basal-bolus insulin in hospitalized adults receiving enteral nutrition were inconclusive. Inpatient diabetes education was associated with lower HbA1c at 3 and 6 months after discharge (moderate certainty) and reduced hospital readmissions (very low certainty). Preoperative HbA1c level &lt; 7% was associated with shorter length of stay, lower postoperative BG and a lower number of neurological complications and infections, but a higher number of reoperations (very low certainty). Treatment with glucagon-like peptide-1 agonists or dipeptidyl peptidase-4 inhibitors in hospitalized patients with type 2 diabetes and mild hyperglycemia was associated with lower frequency of hypoglycemic events than insulin therapy (low certainty). Caloric oral fluids before surgery in adults with diabetes undergoing surgical procedures did not affect outcomes (very low certainty). Counting carbohydrates for prandial insulin dosing did not affect outcomes (very low certainty). Compared with scheduled insulin (basal-bolus or basal insulin + correctional insulin), correctional insulin was associated with higher mean daily BG and fewer hypoglycemic events (low certainty).ConclusionThe certainty of evidence supporting many hyperglycemia management decisions is low, emphasizing importance of shared decision-making and consideration of other decisional factors.